Monitor for topline Phase 2 data from the PIK-201 trial in endometrial cancer, expected by year-end 2026, which is the next major catalyst. The current cash runway supports operations through this readout.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $25.50entry
- T+1 · 3mo ago −3.57%α −3.37% · $24.59
- T+5 · 3mo ago +17.65%α +17.75% · $30.00
- T+20 · 3mo ago +35.33%α +36.57% · $34.51
- T+60 · 20d ago −25.06%α −25.43% · $19.11
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share), compared to a net loss of $4.9M ($3.91/share) in Q2 2025. The company highlighted that topline Phase 2 data for PIKTOR in endometrial cancer remains on track for year-end 2026, and the first patient was dosed in the Phase 1b/2 breast cancer trial. The company has $186.4M in cash and securities, providing runway through key milestones. The filing is a routine quarterly update for a clinical-stage biotech with no revenue and no consensus estimates provided for the current quarter, making it neutral with low impact.
Key Financial Metrics
Key Facts
- Net loss was $16.0M ($2.84/share) for Q2 2026 vs $4.9M ($3.91/share) in Q2 2025.
- Cash, cash equivalents and marketable securities were $186.4M as of June 30, 2026.
- Topline Phase 2 data for PIKTOR in endometrial cancer expected by year-end 2026.
- First patient dosed in Phase 1b/2 trial of PIKTOR in HR+ breast cancer in April 2026.
- Company changed name to Faeth Therapeutics and began trading under ticker FTH on June 16, 2026.
- Stockholders approved conversion of Series B preferred stock into common stock in June 2026.
Financial Impact
Net loss increased to $16.0M from $4.9M YoY; cash position $186.4M provides runway through key clinical milestones.
Risk Factors
- Clinical trial failure or disappointing data for PIKTOR.
- Cash burn rate may require future financing before reaching profitability.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-331563 |
| Document: d168633d8k.htm | 0001193125-26-331563 |
| Document: 0001193125-26-331563-index-headers.html | 0001193125-26-331563 |
| Document: 0001193125-26-331563-index.html | 0001193125-26-331563 |
| Document: 0001193125-26-331563.txt | 0001193125-26-331563 |
| 8-K Data (Synthetic) | 0001193125-26-331563 |
Track record
12 reports on FTH
3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +35.00% at T+60 after the Aug 11, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry price pending
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $10.03 Now $9.28 −7.48% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $12.68 to $12.92 Now $9.28 −26.81% ▲ +1.89% +2.26% vs SPY
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $19.65 to $19.99 Now $9.28 −52.77% ▲ +1.73% +0.08% vs SPY
- Oct 27, 202620d ago 3 Neutral 2/10 Entry $19.20 to $18.75 Now $9.28 −51.67% ▼ −2.34% −1.96% vs SPY
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $19.11 to $19.20 Now $9.28 −51.44% ▲ +0.47% +0.13% vs SPY
- Sep 15, 20268w ago 3 Neutral 2/10 Entry $34.24 to $35.13 Now $9.28 −72.90% ▲ +2.60% +1.47% vs SPY
- Aug 11, 202613w ago 144 Bearish 5/10 Entry $30.00 to $29.38 Now $9.28 +69.07% ▲ +2.07% +2.32% vs SPY
- Aug 4, 202614w ago 8-K Neutral 3/10 Viewing Entry $25.50 to $24.59 Now $9.28 −63.61% ▼ −3.57% −3.37% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers